Evidence map›Paper›PMID 38425406›Full record

ArticleWorld journal of gastrointestinal oncology2024

Anti-EGFR antibody monotherapy for colorectal cancer with severe hyperbilirubinemia: A case report.

Toshiaki Tsurui, Yuya Hirasawa, Yutaro Kubota, Kiyoshi Yoshimura, Takuya Tsunoda

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastrointestinal oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Toshiaki TsuruiDepartment of Medical Oncology, Showa University, Tokyo 1428555, Japan. ttsurui.quantum@gmail.com.
Yuya HirasawaDepartment of Medical Oncology, Showa University, Tokyo 1428555, Japan.
Yutaro KubotaDepartment of Medical Oncology, Showa University, Tokyo 1428555, Japan.
Kiyoshi YoshimuraDepartment of Medical Oncology, Showa University, Tokyo 1428555, Japan.
Takuya TsunodaDepartment of Medical Oncology, Showa University, Tokyo 1428555, Japan.
Showa University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHyperbilirubinemia with hepatic metastases is a common complication and a poor prognostic factor for colorectal cancer (CRC). Effective drainage is often impossible before initiating systemic chemotherapy, owing to the liver's diffuse metastatic involvement. Moreover, an appropriate chemotherapeutic approach for the treatment of hyperbilirubinemia is currently unavailable. CASE SUMMARY: The patient, a man in his 50s, presented with progressive fatigue and severe jaundice. Computed tomography revealed multiple hepatic masses with thickened walls in the sigmoid colon, which was pathologically confirmed as a well-differentiated adenocarcinoma. No

conclusionAnti-EGFR antibody monotherapy is a safe and effective treatment for

Indexed as

Case reportChemotherapyColorectal neoplasmsHyperbilirubinemiaJaundicePanitumumab

Identifiers

PMID38425406
PMCPMC10900148
OpenAlexW4391501274

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.